The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a synthetic corticosteroid to treat certain patients with multiple myeloma. The U.S. Food and Drug Administration...
In the early 1970s, German virologist Harald zur Hausen, MD, FAACR, defied the dogma that cervical cancer was caused by the herpes simplex virus (HSV). He proposed that another virus—the human papillomavirus (HPV)—could lead to cervical cancer. While his initial studies...
As the year draws to a close, we bring you the final edition of Editors’ Picks for 2020. This monthly roundup features one “must read” article, handpicked by the editors, from each journal issue published by the AACR. Studies highlighted in this post include a review article...
The U.S. FDA has approved a new targeted therapy for certain patients with HER2-positive breast cancer who were previously treated with other targeted therapies.
New therapies provide hope and options for people as they monitor and manage this incurable blood cancer.
Sophisticated blood tests offer a less invasive way to characterize cancers, guide treatment and catch recurrences sooner, but tissue biopsies remain the gold standard.
Using deep learning to detect tumor mutations.
Study suggests far-reaching benefits of mental health treatment.
Dental screening before treatment could stave off dental emergencies.
Hypofractionation may allow patients to finish radiation treatment sooner.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More